Sagimet Biosciences (formerly known as 3-V Biosciences) is a biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. It develops treatment for diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company is advancing TVB-2640, an orally bioavailable, FASN inhibitor.